


Assay Procedure

This product is compatible with various types of automated analyzer. An example of the assay procedure is shown.



Basic Performance Data
(Example : Hitachi 7180)

Within-run Reproducibility


	Measurement Value (ng/mL)		
	Level 1	Level 2	Level 3
N	10	10	10
Mean	4.1	51.7	118.7
S.D.	0.08	0.26	0.71
CV(%)	1.94	0.51	0.60
Max.	4.2	52.0	120.0
Min.	4.0	51.1	117.9

Interference

	added volume	measured value (ng/mL)	
		Without interferent	With interferent
Bilirubin F	20 mg/dL	4.7 46.1	4.9 44.7
Bilirubin C	20 mg/dL	5.1 47.8	4.9 46.1
Hemoglobin	500 mg/dL	4.4 44.8	4.7 46.3
Chyle	2400 Formazin Turbidity Unit	4.6 46.1	4.4 42.4
Glucose	4000 mg/dL	5.3 49.4	4.9 47.8
Ascorbic acid*	100 mg/dL	4.4 44.7	4.8 45.2




* Ascorbic acid may interfere with the L-FABP assay from around 100 mg/dL depending on the sample.

Detection Limit



On-board Stability


Please note the On-board stability may differ depending on the type of analyzer and measured environment. When use of this product please preform accuracy control, and calibrate as necessary.



* Parameters to check for prozone effect are required.

Liver - type Fatty Acid Binding Protein (L-FABP) Reagent

NORUDIA L-FABP



For the early detection
of kidney injury

Features

- 1 Ready-to-use liquid reagent
- 2 Applicable to various automated analyzers

For more information contact:



SEKISUI MEDICAL CO., LTD.
Diagnostics Business Unit

1-3, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-0027 JAPAN
Tel: +81-3-3272-0828, Fax: +81-3-3272-0907
E-mail: international@sekisui.com
Web: www.sekisuimedical.jp/english

"NORUDIA" is a trademark owned by SEKISUI MEDICAL CO.,LTD. JAPAN, and is registered in Japan and other countries.

LF-103

1808 JBA1000

Reagent Kit

Name	Assay Principle	Package		Storage
NORUDIA L-FABP	Latex Agglutination Turbidimetry	L-FABP Buffer Solution 1	1 bottle $\times$ 18 mL	2°C - 10°C
		L-FABP Latex Reagent 2	1 bottle $\times$ 7 mL	

Sold Separately

Name	Package	Storage
L-FABP Calibrator	5 concentrations $\times$ 1.0 mL	2°C - 10°C
L-FABP Control	2 concentrations $\times$ 1.0 mL $\times$ 3 vials each	


Other package sizes are available upon request

SEKISUI MEDICAL CO., LTD.

Marker for the early stage detection of kidney injury

What is L-FABP ?


- A fatty acid binding protein found in the renal proximal tubule
- Excreted in the urine due to oxidative stress or renal tubule ischemia before kidney injury
- A useful marker for the early diagnosis of renal disease that involves tubular disorder



Acute Kidney Injury (AKI) - Prediction of onset

Process: 85 cardiovascular surgery patients were divided into AKI and non-AKI cohorts based on the AKIN criteria. Urine L-FABP and Serum CRE were measured immediately before and at several after points surgery.


Results: With the conventional AKI diagnosis method which uses serum creatinine as an indicator, AKI symptoms were confirmed 24 hrs after surgery. However, Urine L-FABP shows a significant increase within the AKI patient cohort immediately after surgery. This indicates that Urine L-FABP is a useful marker for predicting AKI at an early stage.



Diabetic Nephropathy - Early stage diagnosis

Process: The Urine L-FABP levels of 140 Diabetic nephropathy patients were subdivided based on disease stage. The mean and standard deviation values were calculated and compared to those of healthy individuals.

Results: The Urine L-FABP levels of Diabetic nephropathy patients increased with the progress of disease stage. As it shows a significant increase compared to healthy individuals even from the early stages of nephropathy, it can be inferred that L-FABP has utility in the early diagnosis of Diabetic nephropathy.



Chronic Kidney Disease - Monitoring and assessment of treatment

Process: Diabetic nephropathy patients with microalbuminuria were given ARB for 12 months. The Urine Albumin levels, Urine L-FABP levels, and systolic blood pressure were monitored to determine the effects of medical treatment.

Results: Large decrease of Urine Albumin levels, Urine L-FABP levels, and systolic blood pressures were observed after 6 months and 12 months when compared to the start of treatment. Similar to Urine Albumin, Urine L-FABP is effective for the monitoring and assessment of treatment, such as antihypertensive therapy for early-stage diabetic nephropathy.

